Gilead Sciences (GILD) is a Healthcare company in the Drug Manufacturers General industry. It has a market capitalization of $207.00B and a free-cash-flow yield of 4.5%. Over the most recent reported fiscal year, revenue grew 2.4% and free cash flow per share fell 8.2%. Nama's AI scorecard rates it Buy, 6.0 out of 10. On 12-month momentum it ranks in the rising band of its market.
AI scorecard
Buy · 6.0/10
Positive, at the low end of Buy. As of Nov 7, 2026.
Momentum
Rising · +19.0% over 12 months ex. last
Second-best fifth of its market on the past year's move.
Shariah screen
Shariah Compliant
Passes our debt, cash and income screen; not a scholar's ruling.
Off its high
-5.5%
How far the last close sits under the highest price of the past five years.
Market cap
$207.00B
Trailing P/E
—
Price / book
17.5
Price / sales
6.7
FCF yield
4.5%
Dividend yield
2.0%
Gross margin
79.6%
Operating margin
38.5%
Net margin
-10.6%
Revenue growth (YoY)
+2.4%
Revenue growth (3-yr annual)
+2.6%
EPS growth (YoY)
+76.8%
FCF/share growth (YoY)
-8.2%
Beta
0.3
Exchange
NASDAQ
Sector
Healthcare
Industry
Drug Manufacturers General
GILD earnings
Next report: Feb 9, 2027 (Q4 2026, EPS estimate $1.07).
Beat the EPS estimate in 4 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Oct 29, 2026
$2.55
$2.19
+16.4%
$8.30B
Q2 2026
Aug 4, 2026
-$6.75
-$7.25
+6.9%
$7.80B
Q1 2026
May 7, 2026
$2.03
$1.91
+6.3%
$6.96B
Q4 2025
Feb 10, 2026
$1.86
$1.81
+2.8%
$7.92B
GILD analyst price target
Median target $175.00 from 26 analysts, ranging $131.00 – $200.00.
Nama's AI scorecard currently rates Gilead Sciences Buy (6.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does GILD report earnings?
Gilead Sciences's next scheduled report is on Feb 9, 2027. Analysts expect EPS of $1.07.
What is the GILD price target?
The median analyst price target from 26 analysts is $175.00, with a range of $131.00 – $200.00.
Is GILD Shariah compliant?
Nama's AAOIFI-style screen reads Gilead Sciences as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.